A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab (MEDI4736) Plus the Toll-like Receptor Agonist PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers

Trial Profile

A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab (MEDI4736) Plus the Toll-like Receptor Agonist PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Sep 2017

At a glance

  • Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
  • Indications Bladder cancer; Breast cancer; Cutaneous T cell lymphoma; Head and neck cancer; Malignant melanoma; Merkel cell carcinoma; Prostate cancer; Renal cancer; Sarcoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 09 Sep 2017 Trial design presented at the 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
    • 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 24 Apr 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top